Literature DB >> 31108102

Heart Inflammation: Immune Cell Roles and Roads to the Heart.

Francisco J Carrillo-Salinas1, Njabulo Ngwenyama2, Marina Anastasiou1, Kuljeet Kaur1, Pilar Alcaide3.   

Abstract

Heart failure (HF) has been traditionally viewed as a disease of the cardiac muscle associated with systemic inflammation. Burgeoning evidence implicates immune effector mechanisms that include immune cell activation and trafficking to the heart. Immune cell infiltration in the myocardium can have adverse effects in the heart and contribute to the pathogenesis of HF. Both innate and adaptive immunity operate sequentially, and the specificity of these responses depends on the initial trigger sensed by the heart. Although the role of the immune system in the initial inflammatory response to infection and injury is well studied, what sets the trajectory to HF from different etiologies and the role of immunity once HF has been established is less understood. Herein, we review experimental and clinical knowledge of cardiac inflammation induced by different triggers that often result in HF from different etiologies. We focus on the mechanisms of immune cell activation systemically and on the pathways immune cells use to traffic to the heart.
Copyright © 2019 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31108102      PMCID: PMC6717912          DOI: 10.1016/j.ajpath.2019.04.009

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  100 in total

1.  A study of C-reactive protein in the serum of patients with congestive heart failure.

Authors:  S K ELSTER; E BRAUNWALD; H F WOOD
Journal:  Am Heart J       Date:  1956-04       Impact factor: 4.749

2.  Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response.

Authors:  J A S Gomes; L M G Bahia-Oliveira; M O C Rocha; O A Martins-Filho; G Gazzinelli; R Correa-Oliveira
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

3.  Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart.

Authors:  DeLisa Fairweather; Sylvia Frisancho-Kiss; Susy A Yusung; Masheka A Barrett; Sarah E Davis; Shannon J L Gatewood; Dolores B Njoku; Noel R Rose
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

4.  The Trypanosoma cruzi membrane mucin AgC10 inhibits T cell activation and IL-2 transcription through L-selectin.

Authors:  Pilar Alcaide; Manuel Fresno
Journal:  Int Immunol       Date:  2004-08-16       Impact factor: 4.823

5.  Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction.

Authors:  Koichi Kaikita; Takanori Hayasaki; Toshiyuki Okuma; William A Kuziel; Hisao Ogawa; Motohiro Takeya
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

6.  Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

Authors:  Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

7.  Intercellular adhesion molecule 1 deficiency leads to impaired recruitment of T lymphocytes and enhanced host susceptibility to infection with Trypanosoma cruzi.

Authors:  Vladimir Michailowsky; Mara R N Celes; Ana P Marino; Andréa A Silva; Leda Q Vieira; Marcos A Rossi; Ricardo T Gazzinelli; Joseli Lannes-Vieira; João S Silva
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

8.  Widespread myocardial inflammation and infarct-related artery patency.

Authors:  Antonio Abbate; Elena Bonanno; Alessandro Mauriello; Rossana Bussani; Giuseppe G L Biondi-Zoccai; Giovanna Liuzzo; Antonio Maria Leone; Furio Silvestri; Aldo Dobrina; Feliciano Baldi; Franco Pandolfi; Luigi M Biasucci; Alfonso Baldi; Luigi G Spagnoli; Filippo Crea
Journal:  Circulation       Date:  2004-06-21       Impact factor: 29.690

9.  Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.

Authors:  Eugene S Chung; Milton Packer; Kim Hung Lo; Adedigbo A Fasanmade; James T Willerson
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

10.  Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy.

Authors:  André Talvani; Manoel O C Rocha; Lucíola S Barcelos; Yara M Gomes; Antônio L Ribeiro; Mauro M Teixeira
Journal:  Clin Infect Dis       Date:  2004-03-10       Impact factor: 9.079

View more
  29 in total

Review 1.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

2.  The contribution of the cardiomyocyte to tissue inflammation in cardiomyopathies.

Authors:  Van Kim Ninh; Joan Heller Brown
Journal:  Curr Opin Physiol       Date:  2020-10-14

3.  MiR-487b suppressed inflammation and neuronal apoptosis in spinal cord injury by targeted Ifitm3.

Authors:  Dake Tong; Yanyin Zhao; Yang Tang; Jie Ma; Miao Wang; Bo Li; Zhiwei Wang; Cheng Li
Journal:  Metab Brain Dis       Date:  2022-07-08       Impact factor: 3.655

4.  Immunometabolic Mechanisms of Heart Failure with Preserved Ejection Fraction.

Authors:  Gabriele G Schiattarella; Pilar Alcaide; Gianluigi Condorelli; Thomas G Gillette; Stephane Heymans; Elizabeth A V Jones; Marinos Kallikourdis; Andrew Lichtman; Federica Marelli-Berg; Sanjiv Shah; Edward B Thorp; Joseph A Hill
Journal:  Nat Cardiovasc Res       Date:  2022-03-14

5.  Estrogen Receptor-β Agonists Modulate T-Lymphocyte Activation and Ameliorate Left Ventricular Remodeling During Chronic Heart Failure.

Authors:  Rachel Rosenzweig; Vinay Kumar; Sahil Gupta; Oscar Bermeo-Blanco; Matthew S Stratton; Richard J Gumina; Shyam S Bansal
Journal:  Circ Heart Fail       Date:  2022-06-22       Impact factor: 10.447

6.  Immune cell β2-adrenergic receptors contribute to the development of heart failure.

Authors:  Miles A Tanner; Charles A Maitz; Laurel A Grisanti
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-08-20       Impact factor: 5.125

Review 7.  Molecular explanation of Wnt/βcatenin antagonist pyrvinium mediated calcium equilibrium changes in aging cardiovascular disorders.

Authors:  Khalid Saad Alharbi; Yogendra Singh; Obaid Afzal; Abdulmalik Saleh Alfawaz Altamimi; Imran Kazmi; Fahad A Al-Abbasi; Sami I Alzarea; Dinesh Kumar Chellappan; Sachin Kumar Singh; Kamal Dua; Gaurav Gupta
Journal:  Mol Biol Rep       Date:  2022-09-15       Impact factor: 2.742

8.  Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction.

Authors:  Njabulo Ngwenyama; Annet Kirabo; Mark Aronovitz; Francisco Velázquez; Francisco Carrillo-Salinas; Ane M Salvador; Tania Nevers; Venkataraman Amarnath; Albert Tai; Robert M Blanton; David G Harrison; Pilar Alcaide
Journal:  Circulation       Date:  2021-01-19       Impact factor: 29.690

Review 9.  Fibroblast contributions to ischemic cardiac remodeling.

Authors:  Ryan M Burke; Kimberly N Burgos Villar; Eric M Small
Journal:  Cell Signal       Date:  2020-11-02       Impact factor: 4.315

Review 10.  MyD88: At the heart of inflammatory signaling and cardiovascular disease.

Authors:  Abraham L Bayer; Pilar Alcaide
Journal:  J Mol Cell Cardiol       Date:  2021-08-08       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.